Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
EQS-News: Eckert & Ziegler with Strong Sales Growth in the First Quarter of 2023
Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society


DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM

Chemed Corporation to Present at the 2023 RBC Global Healthcare Conference:
Chemed Corporation to Present at the 2023 RBC Global Healthcare Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at approximately 2:35 p.m. (ET)

Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated

The Vanguard Group, Inc.: Mediclinic International plc
The Vanguard Group, Inc.: Mediclinic International plc
The Vanguard Group, Inc.: Mediclinic International plc
Premier, Inc. Evaluating Strategic Alternatives: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Evaluating Strategic Alternatives


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors is evaluating potential strategic alternatives to enhance value

Owens & Minor to Present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor to Present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023


Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services, announced today that Ed

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
EQS-News: Eckert & Ziegler: Recognized Australian Endocrine & Hypertension Center Joins International Groups with a Clinical Trial of PentixaPharm’s Primary Aldosteronism Lead Candidate
Owens & Minor Reports First Quarter 2023 Financial Results: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Reports First Quarter 2023 Financial Results


Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the first quarter ended March 31, 2023.



Key Highlights:




  • Consolidated revenue of $2.5 billion in the first quarter


  • Net

Inogen Announces First Quarter 2023 Financial Results: https://mms.businesswire.com/media/20220804005173/en/622619/5/Inogen_Logo_300_DPI.jpg
Inogen Announces First Quarter 2023 Financial Results


Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31

Acadia Healthcare to Participate in BofA Securities Healthcare Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in BofA Securities Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the BofA Securities 2023 Healthcare Conference, May 9-11, 2023, in Las Vegas, Nevada.



In

Humana and Longevity Health Partner to Expand Access to Special Needs Plans for Medicare Beneficiaries: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana and Longevity Health Partner to Expand Access to Special Needs Plans for Medicare Beneficiaries


Longevity Health Plan and Humana Inc. (NYSE: HUM) today announced a new partnership to expand special needs health plan offerings that support the unique requirements of Medicare-eligible

Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye:
Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye


Agilent Technologies Inc. (NYSE: A) announced today that Dr. Jiangbin Ye has received an Agilent Solutions Innovation Research Award (SIRA). The award supports drug discovery and development

EVO ICL Sponsors Jonas Brothers’ The Tour: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
EVO ICL Sponsors Jonas Brothers’ The Tour


EVO ICL, the vision correction procedure that works in harmony with your natural eye, provides sharp, clear vision day or night and does not cause contact lens induced dry eye or dry eye syndrome

EQS-News: MediClin AG: Encouraging development of Group sales in the first quarter of 2023
EQS-News: MediClin AG: Encouraging development of Group sales in the first quarter of 2023
EQS-News: MediClin AG: Encouraging development of Group sales in the first quarter of 2023
EQS-News: MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
EQS-News: MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
EQS-News: MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
STAAR Surgical Reports First Quarter 2023 Results: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Reports First Quarter 2023 Results


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023

NanoString Technologies Releases Operating Results for First Quarter of 2023: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Technologies Releases Operating Results for First Quarter of 2023


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the first quarter ended March

QuidelOrtho Reports First Quarter 2023 Financial Results: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Reports First Quarter 2023 Financial Results


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Chemed Corporation to Present at the Bank of America Merrill Lynch 2023 Health Care Conference:
Chemed Corporation to Present at the Bank of America Merrill Lynch 2023 Health Care Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Merrill Lynch 2023 Health Care Conference on Wednesday, May 10, 2023, at 10:40 AM (PDT) at

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International PLC
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International PLC
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International PLC
Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028


DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private

Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a study “Cost-Effectiveness of a

Owens & Minor Announces First Quarter 2023 Earnings Release Date and Conference Call: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor Announces First Quarter 2023 Earnings Release Date and Conference Call


Owens & Minor, Inc. (NYSE: OMI) plans to release financial results for the first quarter of 2023 on Friday, May 5, 2023, before trading begins on the New York Stock Exchange.



The Company will